EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Global cancer burden attributable to tobacco smoking in 2022: a differential analysis by smoking status, sex, and development level

Veer Shah, Darshi Shah, Karan Shah, Jeanne Wu, Daniele Bruno, Paolo Boffetta, Monireh Sadat Seyyedsalehi

International Journal of Epidemiology · 2026-10-14 · 55 (6)

DOI: 10.1093/ije/dyag239 ↗
AbstractBibliografische Angaben

Abstract

Abstract Background Tobacco smoking is a leading preventable cause of cancer. We estimated its attributable cancer burden by smoking status (current vs. former), further stratified by cancer type, sex, country, and Human Development Index (HDI). Methods The Population Attributable Fraction (PAF) for cancer incidence and mortality due to tobacco were estimated across 175 countries by using 2000 Global Burden of Disease smoking prevalence and 2022 Global Cancer Observatory cancer data. Relative risks (RRs) were derived from large pooled and meta-analyses, and population data from the World Bank. Countries were categorized by HDI. Results The global tobacco PAF was 17.2% for cancer incidence and 22.4% for mortality. Lung cancer had the highest RR for current smokers (8.96) and laryngeal cancer for former smokers (4.65). Males had a higher cancer incidence (26.1%) and mortality (32.1%) burden than females (8.0% and 10.2%, respectively). Cancers with the highest smoking PAF were laryngeal (70.1%), lung (66.9%), pharyngeal (63.5%), oral cavity (38.5%), and bladder (39.4%). PAF estimates for incidence were 5.4% in low-HDI (49 countries), 15.0% in medium-HDI [41], 19.3% in high-HDI [32], and 17.4% in very-high-HDI [32] countries; corresponding mortality estimates were 6.4% (low-HDI), 17.4% (medium-HDI), 26.0% (high-HDI), and 23.6% (very-high-HDI), respectively. Conclusion Approximately one in six cancer cases and one in four cancer deaths globally are attributable to tobacco smoking. Despite declining smoking prevalence, former smokers account for a substantial burden long after cessation. Males and higher-HDI countries bear a greater burden.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →